Renata (DHA:RENATA) Debt-to-Equity : 0.52 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Renata Debt-to-Equity?

Renata's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was BDT12,734 Mil. Renata's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was BDT4,260 Mil. Renata's Total Stockholders Equity for the quarter that ended in Mar. 2024 was BDT32,530 Mil. Renata's debt to equity for the quarter that ended in Mar. 2024 was 0.52.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Renata's Debt-to-Equity or its related term are showing as below:

DHA:RENATA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.19 Max: 0.71
Current: 0.52

During the past 13 years, the highest Debt-to-Equity Ratio of Renata was 0.71. The lowest was 0.08. And the median was 0.19.

DHA:RENATA's Debt-to-Equity is ranked worse than
66.98% of 851 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs DHA:RENATA: 0.52

Renata Debt-to-Equity Historical Data

The historical data trend for Renata's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renata Debt-to-Equity Chart

Renata Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.14

0.19

0.30

0.47

Renata Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.46	0.47	0.49	0.47	0.52

Competitive Comparison of Renata's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Renata's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renata's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Renata's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Renata's Debt-to-Equity falls into.

Renata Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Renata's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10878.813	+	3401.914)	/	30608.738
	=	0.47

Renata's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(12733.572	+	4259.706)	/	32530.355
	=	0.52

Renata (DHA:RENATA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Renata Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Renata's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Renata (DHA:RENATA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Renata PLC (DHA:RENATA) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Plot Number 1, Milk Vita Road, Section-7, GPO Box No. 303, Mirpur, Dhaka, BGD, 1216

Website

https://www.renata-ltd.com

Renata Ltd is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.

Renata (DHA:RENATA) Headlines

No Headlines